Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
3 Articles
3 Articles
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.
Moderna. PHOTO: @moderna_tx A personalized experimental cancer vaccine developed by Merck and Moderna showed positive results in a phase 3 clinical trial in patients with high risk or advanced melanoma. This progress brings companies closer to a possible application for approval with regulatory authorities. The treatment, based on messenger RNA technology (MRNA), was evaluated in combination with Keytruda, Merck's immunotherapy, in more than 1,1…
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial results.A recent late-stage clinical trial showcased a combination therapy comprising MRNA’s intismeran autogene and MRK’s renowned Keytruda as effective in high-risk patients with melanoma.And the landmark top-line results position Merck shares for a …
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
